All posts by imreal

The Healthcare Technology Report’s Top 25 Healthcare Technology CTOs of 2022


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology CTOs of 2022. Chief Technology Officers are indispensable to the success of companies operating in the healthcare technology space. Not only do they oversee teams comprised of engineers, software developers, chemists, scientists, and others, but they enable their management teams to pursue some of the most advanced technological visions, while setting the path for research & development and ultimately shepherding innovations from idea to market. The companies represented on this list deliver a variety of solutions, from software to medical devices to virtual care, but what they have in common is the backbone of revolutionary technology supporting them.

The distinguished leaders on this year’s list include Achin Bhowmik, CTO and EVP of Engineering at Starkey, who is responsible for the company’s technology strategy, while also leading the drive to transform hearing aids into multifunctional health and communication devices. Meanwhile, Gaurang Patel, VP of IT for Revance, is building a critical technology solutions infrastructure to drive operational advancement as the company transitions from a clinical research and development company to a large-scale commercial organization. And Abhi Verma, CTO of SOPHiA GENETICS, leads the team that builds and operates the SOPHiA DDM™ Platform, an AI and ML-powered global cloud-based platform that provides an instantly accessible environment to standardize, compute, and analyze digital health data.

This year’s awardees represent some of the most innovative healthcare technology companies in the world, from pharmaceuticals to electrotherapy, digital therapeutics, immunotherapy, and many other specialties. Please join us in celebrating The Top 25 Healthcare Technology CTOs of 2022.

Tarun Mathur (Indegene), Aviva McPherron (NuVasive), Achin Bhowmik (Starkey), Maysara Rabah (Tabuk Pharmaceuticals), Scott Burke (Verily), Michael Majoue (Zynex Medical), Alo Sarv (SOCi), Gaurang Patel (Revance), Kyle Ryan (Tebra), Abhi Verma (SOPHiA GENETICS), Ed Tourtellotte (4G Clinical), Frederick Peguero (WorkCare), Shawn Walker (Veranova), Pawan Parihar (Reata Pharmaceuticals, Inc.), Varun Ganapathi (AKASA), David Kiklis (Replimune), Chetan Uberoy (MphRx), Nigel Webster (WELL Health Technologies), Charlie Wen (ulab Systems, Inc.), Michael Baglio (Protenus), Nick Gianadda (Quadrant Biosciences), Kunaal Naik (Memora Health), Josh Siegel (SameSky Health), Justin French (AngelEye Health), Adam Yala (metaMe Health).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email:

Vericle Chooses MeldRx™ by Darena Solutions to Meet Cures Act Requirements


MeldRx enables us to focus on our core competence – delivering best-in-class EHR software – by leveraging their certified FHIR API technology instead of duplicating efforts to build, maintain, and certify those APIs.” – EREZ LIROV CTO, VERICLE

MeldRx™ is a comprehensive Ecosystem developed by Darena Solutions for EHRs, providers, and their patients. This Ecosystem includes the ONC Certified FHIR® API that allows EHRs to meet all the certification mandates and future-proofs them from evolving regulatory and interoperability requirements. The ecosystem relieves practitioners from the burdens of integration, interpreting regulations, finding solutions, and staff disruption.

“MeldRx enables us to focus on our core competence – delivering best-in-class EHR software – by leveraging their certified FHIR API technology instead of duplicating efforts to build, maintain, and certify those APIs,” comments Erez Lirov, CTO, Vericle.

“We are proud to be working with the Vericle team. Our combined effort is helping to enhance the patient experience by enabling their providers to meet the “Certify and Provide” mandates for the (g)(10) FHIR® API, as well as sharing the complete Electronic Health Information (EHI),” says Wayne Singer, VP of Regulatory Services, Darena Solutions.

ABOUT VERICLE

Vericle, is the leading national provider of Practice Management Software. Vericle Provides EMR/EHR software, Administrative reporting software, and medical billing software. Vericle partners with several billing companies including ClinicMind and Billing Dynamix to provide comprehensive practice management services that include full-service billing. For more information, visit http://www.vericle.net or http://www.clinicmind.com

ABOUT DARENA SOLUTIONS

Darena Solutions delivers an Ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to EHRs, providers, and payers. By creating channels for data sharing between providers, payers, and patients, Darena enables healthcare organizations to achieve compliance and derive insights for prospective decision-making resulting in better patient outcomes. For more information, visit: http://www.darenasolutions.com. You can connect with us on LinkedIn and Twitter.

Share article on social media or email:



How one Pharmaceutical Company Gained Incredible Results, Upcoming Webinar Hosted by Xtalks


Register for this webinar and take an inside look at ORIC Pharmaceuticals’ brilliant eQMS decision matrix.

Deciding to replace or purchase an eQMS has far-reaching consequences. The right choice can save a company’s quality department thousands of dollars and hours, making the team a hero, but a poor one can result in considerable user frustration and negative ROI.

Register for this webinar and take an inside look at ORIC Pharmaceuticals’ brilliant eQMS decision matrix. See how they compared, selected, implemented, customized, validated and launched their eQMS quickly, with incredible results.

Attendees will gain insights into: How ORIC carefully weighed the pros and cons of several leading quality systems — and why the most popular one was far from their first choice; Tips for getting the best price on eQMS, including pricing pitfalls to avoid; Secrets for a smooth implementation with the least disruption in day-to-day routines; Why out-of-the-box configurations rarely work, and how Intellect helped ORIC avoid wasted time, restructuring of processes and user frustrations.

Join Melody Puckett, Sr. Manager of Quality Assurance, ORIC Pharmaceuticals; and Brooke Jackson, Quality Assurance Specialist, ORIC Pharmaceuticals, for the live webinar on Tuesday, December 6, 2022, at 1pm EST (10am PST).

For more information, or to register for this event, visit Choosing the Right eQMS: How one Pharmaceutical Company Gained Incredible Results.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

University of Medicine and Health Sciences Presents “Alzheimer’s Disease & Exploring Research in Medical School”


News Image

“Research is a way of thinking about questions. How do we approach a problem and figure out what we can do? In medicine, the best information we have now is through clinical trials of what does and doesn’t work.” – Dr. D. Craig Ayre

The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, has published the video recording of its recent panel discussion, “Alzheimer’s Disease & Exploring Research in Medical School.” The event featured Dr. Craig Ayre, UMHS Associate Professor of Molecular Science, and Nihal Satyadev, a fourth-year medical student at UMHS and Co-founder of The Youth Movement Against Alzheimer’s, a nonprofit organization dedicated to promoting understanding of Alzheimer’s among youth and young adults by providing opportunities to help those affected by the disease. The discussion centered around the value of student research, connecting passion with research, and emerging trends in research and treatment for diseases like Alzheimer’s Disease. A recording of the event has been posted to the UMHS Live Events and Meetings page.

UMHS planned the livestreamed event to coincide with Alzheimer’s Awareness Month. Each November, organizations including The Alzheimer’s Foundation of America, plan events to raise awareness of Alzheimer’s disease and show support for more than 6.2 million Americans living with the disease. During the discussion, Nihal described his work as a volunteer, advocate, and student researcher focused on advancing understanding of the disease and finding a cure, and Dr. Ayre shared why student research sharpens critical thinking, advances clinical understanding, and the promise of discovery.

“Research is a way of thinking about questions,” said Dr. Ayre. “How do we approach a problem and figure out what we can do? In medicine, the best information we have now is through clinical trials of what does and doesn’t work.“

As a medical student, Nihal Satyadvev pursued his passion for finding a cure for Alzheimer’s Disease. While studying at UMHS, Nihal worked on a project in the anatomy lab and published case reports that qualified him to apply for a National Institutes of Health summer research internship. Based on his previous research, Nihal was awarded a grant to work at UCSD studying gene therapy for treating the neurodegenerative disorder.

“Alzheimer’s is the biggest threat to our healthcare system: 6.2 million people have Alzheimer’s, and 40% of their caregivers are diagnosed with depression,“ said Nihal. “[Gene therapy] is promising, but with all things Alzheimer’s we have to be patient and maintain hope.”

During the discussion, Dr. Ayre, who serves as Chair of the UMHS Research Department, described how gene therapy is providing a revolutionary approach to treating diseases in a way that was not previously possible – improving the prognosis for once-deadly diseases. He also shared advice for medical students interested in pursuing research opportunities and described emerging trends in research.

“The problems we’re tackling now in medicine are ones two or three generations ago we didn’t know existed,” said Dr. Ayre. He also offered the following advice, “Research is an act of passion. Find someone you want to work with and learn from them”

The talk was the latest in a series of live stream events featuring UMHS students, faculty, and alumni sharing their expertise on topics targeted toward current and prospective medical students and healthcare professionals. Past events include:

“Primary Care Spotlight: What is a Hospitalist?”

“Women’s Cancer Awareness: Doctors Discuss Ovarian, Cervical, and Breast Cancer Screening”

“Closing the Deaf Gap in Healthcare: Giving a Voice To Deaf Patients”

“Rural Medicine: Making a Difference in Underserved Areas”

“Non-Traditional Medical Student Livestream: A Student’s Perspective”

“LGBTQ+ Medicine & Theory”

“Pathways to Practicing Medicine in Canada: UMHS Alumni Share Their Experiences”

“UMHS Women in Medicine: A Conversation About the First Year of Residency,”

“Cardiology: A Discussion About Cardiac Care & Careers in Cardiology,”

“Black Women in Medicine: A Conversation About the Black Experience”

“Ask a Microbiologist,” and

“Suicide Prevention and the State of Psychiatry”

Links to view all past discussions may be found by visiting the UMHS live events and meetings page.

About UMHS

The University of Medicine and Health Sciences (UMHS), is a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada. UMHS was founded in 2007 by medical education pioneers Warren and Robert Ross to deliver a highly personalized school experience. Graduates of UMHS earn a Doctor of Medicine degree (MD) and qualify to practice medicine throughout the United States and Canada. Students begin their Basic Science studies in St. Kitts, West Indies, and complete their clinical training in the United States. With an unprecedented 96% student retention rate, the vast majority of students that begin their medical studies at UMHS go on to obtain residencies. For more information, visit https://www.umhs-sk.org/.

Share article on social media or email:

MOLLI Surgical Named to Fast Company’s Second Annual List of the Next Big Things in Tech


News Image

MOLLI Surgical’s wire-free and radiation-free breast cancer localization technology has been named to Fast Company’s second annual Next Big Things in Tech list. The award honors technology breakthroughs that promise to shape the future of their industries — from agriculture and environment to productivity and artificial intelligence. MOLLI Surgical has been recognized in the health category for its cutting-edge advancements in simplifying precision surgery to deliver an improved patient experience.

Marking the lesion for those needing breast cancer surgery has traditionally been a difficult experience for the patient — typically using a wire on the same day of surgery. MOLLI® is the smallest localization device on the market that precisely and reliably marks where the lesion is for the surgeon to remove it. The device is easy to use, reliable, and extremely precise, delivering an improved patient experience and better cosmetic results.

“Technology breakthroughs and cutting-edge advancements promise to be the solution to some of the world’s most pressing issues. Fast Company is excited to highlight some of the organizations, of all sizes and industry backgrounds, whose technology advancements today will lead to a better tomorrow,” says Brendan Vaughan, editor-in-chief of Fast Company.

MOLLI provides immense benefits to both patients and caregivers. The MOLLI Marker® — about the size of a sesame seed — can be detected using the MOLLI Wand® and its position is displayed like GPS visually with the MOLLI Tablet®. Because it’s the smallest localization device, the MOLLI Marker can deliver greater precision for marking and removing lesions, which means more surgical options for patients.

“What an incredible honor,” said Ananth Ravi, Ph.D., President, and CEO of MOLLI Surgical Inc. “Years ago, we listened to one patient who shared her story on the traditional wire localization method — specifically, the anxiety, pain, and discomfort she experienced while waiting for surgery. Listening to her inspired both the device and the company. Since then, we have been laser-focused on helping hospitals achieve even greater efficiencies and deliver a better overall patient experience.”

MOLLI Surgical is dedicated to creating devices that dramatically reduce the burden of treatment on patients, provide confidence to care teams and improve the efficiencies of health systems. To learn more, please visit mollisurgical.com.

Click here to see the final Next Big Things in Tech list, which will be included in the Winter 2022/2023 issue of Fast Company hitting newsstands on December 6.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About MOLLI Surgical

MOLLI Surgical started in the operating room, where surgeons were using dated tools to treat cancer patients — and we knew we could do better. Our surgical wand is precise, reliable, easy to use, and built with the realities of the operating room in mind. More importantly, it is built with patients in mind. Our technology replaces procedures to mark lesions with one that is more precise, efficient, and cost-effective. MOLLI Surgical is proud to build the advanced equipment that patients prefer to have and that physicians prefer to use. Follow us on Facebook, LinkedIn, Twitter, and YouTube.

Share article on social media or email:



Events Will Recognize First-Ever World Movement Disorders Day on November 29, 2022


The first-ever World Movement Disorders Day will be November 29, 2022.

The first-ever World Movement Disorders Day will be November 29, 2022.

Movement disorders are some of the most complex diseases to treat, diagnose and understand. In order to increase global awareness of this sub-specialty among healthcare professionals and the general population, the International Parkinson and Movement Disorder Society (MDS) is launching the first World Movement Disorders Day on November 29, 2022.

Building on an educational social media campaign throughout the month, MDS will present two live virtual events with leading movement disorders experts November 29, one event in each hemisphere. Global leaders in the field will discuss what movement disorders are, misconceptions about them, and why they are so complex to treat, diagnose and understand.

“Movement Disorders include a variety of complex medical conditions that affect a large and growing number of people,” said Francisco Cardoso, MDS President. “By increasing awareness of these difficult-to-diagnose diseases, it will be possible for more people to connect with professionals who have the specialized knowledge to provide proper diagnosis and management. We hope that many partners will join us in observing this new annual event.”

Event details:

Eastern Hemisphere Event

Live on Zoom, 2:00 GMT

Details and registration: https://us06web.zoom.us/webinar/register/WN_bLNT6HrKTA6THBajkafSbQ

Western Hemisphere Event

Live on Zoom, 18:00 GMT

Details and registration: https://us06web.zoom.us/webinar/register/WN_NNX95jN4Sk2deXPt5JOClQ

The date November 29 was chosen to honor French neurologist, Jean-Martin Charcot, who is considered by many to be a pivotal influence on the study of movement disorders.

All global partner organizations, healthcare professionals and patients in the movement disorders community can help MDS to boost global awareness by sharing on social media using #MoveDisorder. More information and digital assets can be found at http://www.movementdisorders.org/day.

# # #

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

AmunBio to Present Scientific Data for AMUN-003 at the 2022 San Antonio Breast Cancer Symposium (SABCS)


News Image

Pre-clinical data, to be presented at SABCS, shows that AMUN-003 demonstrated single agent safety and efficacy in TNBC. The same model shows how combination therapy with immune Checkpoint Inhibitors synergizes with the AMUN-003, resulting in significant inhibition of further metastatic spread.

AmunBio, Inc., an early, pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, today announced a presentation, on Tuesday, December 6, 2022, at the 45th annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx., of the pre-clinical study results of AMUN-003, an investigational, first-in-class, immuno-oncologic adenovirus being developed for the treatment of multiple solid tumors, including aggressive, metastasized, triple-negative breast cancer (TNBC).

The development of oncolytic viral therapies, which represents a unique therapeutic paradigm within Immuno-Oncology, promises a new approach for the treatment of human cancers. AmunBio has developed a proprietary platform technology that has the potential to generate a strong pipeline of patient-centric next-generation engineered immunotherapeutic oncolytic viruses for the treatment of cancer, including triple-negative breast cancer (TNBC) and hematological malignancies.

“I believe that AmunBio’s platform technology will result in a fundamental shift of the treatment of human cancers, augmenting existing and novel treatment modalities, compared to what is possible today,” said V.K. Gadi, MD, Ph.D., Deputy Director of University of Illinois Cancer Center, and a lead scientific advisor to AmunBio.

“Inside their microenvironment, many advanced solid cancers, including TNBC are hostile to the immune system and greatly minimize the effectiveness of immunotherapy. AMUN-003 is an advanced generation oncolytic adenovirus that selectively enters cancer cells followed by viral reproduction and destruction of the cancer cell on exit,” Gadi added.

“During cellular infection, AMUN-003 has been engineered to produce two proteins that stimulate the immune response (GM-CSF) and sequesters an inhibitor of the immune response (TFF-b). Our data, which will be presented at SABCS this year, shows that in a highly aggressive TNBC model AMUN-003 demonstrates single agent safety and efficacy. Moreover, in the same TNBC model, combination therapy with immune Checkpoint Inhibitors synergizes with the AMUN-003, resulting in significant inhibition of further metastatic spread. Additional pre-clinical studies are underway to advance this technology into clinical trials,” Gadi concluded.

Presentation details


  • Poster ID: PD2-03
  • Poster Title: Targeting TFF-b and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in triple-negative breast cancer (TNBC)
  • Date/Time: December 6, 2022, 5:00 PM – 6:15 PM CST

The San Antonio Breast Cancer Symposium (SABCS), which takes place December 6-10, 2022, in San Antonio, Tx, is the premier conference for basic, translational, and clinical cancer research professionals and provides state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease.

About Breast Cancer

Breast cancer remains the most common diagnosed cancer in women and the second most common cancer overall. [1][2][3] Over 2.3 million new cases and 685,000 deaths from breast cancer occurred in 2020 and experts predict that by 2040 the burden of breast cancer will increase to over 3 million new cases and 1 million deaths every year because of population growth and aging alone.[4]

About Triple-negative Breast Cancer (TNBC)

Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, accounts for approximately 15% of all cases of breast cancers diagnosed worldwide. This subtype of breast cancer is associated with poor prognosis, as defined by low a five-year survival and high recurrence rates after adjuvant therapy. [5] TNBC, which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR) and has only limited or no human epidermal growth factor receptor 2 (HER2) expression, is, unlike other subtypes of breast cancer (i.e., ER+, HER2+), more commonly diagnosed in women younger than 40 years, and disproportionately affects black women. [6] Because TNBC is not sensitive to endocrine therapy or HER2 treatment, effective standard treatment options are extremely limited. Since there are no approved targeted treatments available for the TNBC today, there is an urgent medical need to develop new treatment strategies. [7]

About AMUN-003

AMUN-003 is an investigational, first-in-class, Immuno-Oncologic adenovirus being developed for the treatment of multiple solid tumors, including aggressive, metastasized, triple-negative breast cancer (TNBC), melanoma, and other solid tumors. AMUN-003 blocks suppression of the immune response inside the tumor, stimulates the recruitment of cancer-killing immune cells and avoids non-specific inflammation. Preclinical studies with AMUN-003 in breast cancer alone, compared to prior oncolytic virus constructs, have demonstrated near-complete breast cancer inhibition. Furthermore, in preclinical studies, a single dose of AMUN-003 delayed the progression of TNBC, while a single dose of the investigational drug, in combination with Checkpoint Inhibitors, demonstrated significant inhibition of subcutaneous tumor growth and a more durable anti-cancer response. Based on these preclinical findings, treatment with AMUN-003 may lead to long-term protection from cancer recurrence. Following a planned Investigational New Drug (IND) application, which is expected in early 2023, AmunBio is planning multiple Phase 1 clinical trials of AMUN-003, alone or in combination with Checkpoint Inhibitors, in triple-negative breast cancer (TNBC), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Bladder cancer and Head & Neck Cancer, to start in late 2023/early 2024.

About AmunBio

AmunBio is an early-stage biotechnology company developing and commercializing novel, cutting-edge, next-generation engineered immunotherapeutic oncolytic viruses for the treatment of cancer. With the novel, next-generation, proprietary technology platform approach, utilizing direct destruction of cancer cells and immune system activation, patients will be uniquely positioned to defeat cancer. For more information, go to https://amunbio.com/ and follow @AmunbioI

Reference

[1] World Cancer Research Fund (WCRF)/Statistics

[2] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Sep 2;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub ahead of print. PMID: 36084384; PMCID: PMC9465273.

[3] Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1214-1222. doi: 10.1158/1055-9965.EPI-18-0098. Epub 2018 Aug 1. PMID: 30068516; PMCID: PMC8423092.

[4] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.

[5] de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. PMID: 21069385; PMCID: PMC3018596.

[6] Doepker MP, Holt SD, Durkin MW, Chu CH, Nottingham JM. Triple-Negative Breast Cancer: A Comparison of Race and Survival. Am Surg. 2018 Jun 1;84(6):881-888. PMID: 29981619.

[7] Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. PMID: 32517735; PMCID: PMC7285581.

Source: AmunBio, Inc.

RGB Architects Announces Support of Dare to Dream Ranch with Upcoming Pro Bono Projects


News Image

Those looking to learn more about The Dare to Dream Ranch or donate to the cause should visit DaretodDreamRanch.org.

The Dare to Dream Ranch in Foster, Rhode Island provides alternative therapy programs for U.S. Military veterans and their families struggling with emotional challenges such as Post Traumatic Stress Disorder (PTSD), Anxiety, Depression, Military Sexual Trauma (MST) and Mild Traumatic Brain Injury (TBI). As a Veteran owned business, RGB Architects is thrilled to support the work being done at the Dare to Dream Ranch with pro bono design work for two upcoming projects.

The first design project being completed by RGB Architects for The Dare to Dream Ranch is for a Gift Shop. The Gift Shop will sell products that veterans and their spouses create in therapy. Not only do the Veterans benefit from the sale of the products but the residual income will support additional non-profit programs.

The second design project being completed by RGB Architects is a new Health and Wellness Center. The Health and Wellness Center at the Dare to Dream Ranch will have two rooms to add massage, reflexology, reiki and hypnotherapy to the Ranch’s programs. The Center will also feature attached stalls, so veterans will no longer need to cancel their visits due to the weather.

RGB Architects partner, David DeQuattro, is thrilled to provide the designs for these two projects and gather friends who were able to conduct all structural, mechanical and environmental engineering. DeQuattro is now looking to spread the word regarding the fundraising of $100,000 to get these buildings built for our great veterans.

The Dare to Dream Ranch has announced the following donation incentives:


  • $500,000 Naming Rights for the Health and Wellness Center
  • $100,000 Naming Riding Arena Area
  • $50,000 Naming Rights for the Mental Health Clinic
  • $25,000 Naming one of the medical offices for massage, reflexology, reiki and hypnotherapy


$15,000 Naming one of the horse stalls

Those looking to learn more about The Dare to Dream Ranch or donate to the cause should visit DaretodDreamRanch.org.

About RGB Architects:

RGB Architects is one of the leading architecture, interior design, and master planning firms in the New England area, with a reputation for design excellence since 1946 and a portfolio that includes some of the most important architectural accomplishments in the area. RGB is a veteran owned firm supporting veterans not only through projects but also hiring them and was a founding member of the U.S. Green Building Council (http://www.usgbc.org) Rhode Island Chapter. With a record of commissions for eight of the largest buildings in the state’s capital the RGB name is recognized respectfully.

Share article on social media or email:

RIT professors co-author study on detecting fake Amazon reviews


graphic featuring an overlay of a 4.5 star customer review on a person typing on a laptop.

New research co-authored with others by two Saunders College of Business faculty researchers provides one method for searching out five-star fakes. (Shutterstock)

It doesn’t have to be the holidays for Amazon to receive a lot of attention from product buyers, but business on the nation’s largest online retailer is especially brisk this time of year.

While the company says it has over 12,000 employees who look for fraud on its site, the growing glut of fake reviews leaves one wondering whether that device or accessory you’re considering is truly so highly rated.

New research co-authored with others by Ali Tosyali and Gijs Overgoor, assistant professors in the Department of MIS, Marketing, and Analytics at RIT’s Saunders College of Business, provides one method for searching out five-star fakes.

In the study, titled, “Detecting Fake Review Buyers Using Network Structure: Direct Evidence from Amazon,” Tosyali and Overgoor:


  • Employed network science and machine learning to develop a highly accurate method for detecting fake reviews.
  • Revealed that products that purchase fake reviews share a common set of reviewers, predominantly among Facebook groups, which are highly clustered in a product-reviewer network.
  • Claim their research method is highly accurate and, unlike approaches relying on reviews’ text, their approach is more resistant to manipulation by sellers.

The research, featured in The Wall Street Journal earlier this year, offers a promising means of helping consumers avoid being duped by these fraudulent and misleading reviews. The paper has been published on pnas.org.

The two RIT professors became involved in the research after Tosyali’s personal experience purchasing a vitamin on Amazon. “The product I purchased had many reviews—approximately 5,000—with an average rating of 4.9,” Tosyali recalled. “After using it, I observed some side effects and returned the product.”

Upon returning the product, Tosyali looked at the reviews more closely and saw many negative comments, which referenced the side effects he experienced.

“However, because of the large number of five-star reviews, the product looked pretty satisfactory,” Tosyali observed. “At that point, I wondered if there was a way to detect fake reviews that mislead customers.”

During a follow-up conversation with Overgoor, Tosyali mentioned his experience and the two Saunders College faculty decided to look into the issue more closely.

Overgoor later discovered that some UCLA colleagues had initiated a paper analyzing the market of fake reviews using a dataset of Amazon reviews, and the researchers agreed to collaborate.

The dataset used took about nine months to collect, with the help of UCLA undergrads who infiltrated Facebook groups where fake reviews are solicited. After identifying sellers and products for which faux reviews were gathered, all reviews were then combined together. The research took about a year, employing techniques from network science, machine learning, and text and image analysis.

Based on their research, Tosyali and Overgoor offer the following tips for consumers to spot fake Amazon reviews.

  • Compared to products not buying fake reviews, products that purchase fake reviews are highly connected and clustered in the network, implying that products buying fake reviews tend to have more reviewers in common than other products.
  • While regular products receive their reviews from a dispersed set of millions of Amazon customers, products purchasing fake reviews must rely on the relatively small number of reviewers participating in the “fake review marketplace.”
  • Features derived from the product-reviewer network are especially useful for detecting fake reviews because—in addition to being more predictive than text or metadata features—they are more difficult or costly to manipulate by sellers than text or review timing.

According to the RIT researchers, e-commerce platforms can use the research “as a flagging mechanism,” and “the research increases customers’ awareness of these harmful initiatives.”

“They could be more vigilant about five-star reviews and be aware that five-star reviews could be paid,” Tosyali said.

The team is working on additional research on this topic, Overgoor added.

Share article on social media or email:

Youth receive nutritional support at Don Bosco Kansebula thanks to donor funding from Salesian Missions


News Image

DR CONGO: Youth receive nutritional support at Don Bosco Kansebula thanks to donor funding from Salesian Missions.

Don Bosco Kansebula also has a 44-hectare farm that supplies food.

More than 360 youth received nutritional support at Don Bosco Kansebula, located in Lubumbashi, Democratic Republic of the Congo*, thanks to donor funding from Salesian Missions, the U.S. development arm of the Salesians of Don Bosco.

Youth benefiting from this food were ages 6-22. Many are are in secondary school and college as well as 82 young Salesians studying at Don Bosco Kansebula. Single mothers from the villages also received this donation. The goal was to provide ongoing balanced nutrition for young Salesians and other vulnerable youth.

Don Bosco Kansebula also has a 44-hectare farm that supplies food for the Salesian formation house and to the village nearby. Since its beginning, Don Bosco Kansebula has provided young Salesians with philosophy education and has given them shelter and nutritional support while at the school. Villagers living near Don Bosco Kansebula have used the farm to cultivate food for themselves and the community.

One of the beneficiaries was Kyundundu Mbilizi Fabrice, who is 25 and in high school, Fabrice said, “I studied agriculture in the eastern part of the Democratic Republic of the Congo at Uvira. Now, I am at Kansebula as Salesian of Don Bosco in post-novitiate. At Kansebula, we have a garden and we produce vegetables and keep some domestical animals. Villages and confreres have benefited from what is produced in the garden and in the farm as well. I am really happy for what our benefactors are doing for us in order to fight hunger and I encourage them to continue in that direction.”

Salesian missionaries have been working in the Democratic Republic of the Congo for more than 100 years ensuring that the most vulnerable children are not forgotten. Salesian primary and secondary schools and programs lay the foundation for early learning while Salesian trade, vocational, and agricultural programs offer many youth the opportunity for a stable and productive future.

Despite its vast material wealth, the Democratic Republic of the Congo has long been a very poor nation. Half of the country’s population lives below the poverty line, living on less than $1 a day, especially those in rural communities. Because of ongoing strife and violence within the country, more than 8.5 million people are in urgent need of humanitarian assistance. More than 4.1 million Congolese are now displaced, with 620,000 seeking refuge in neighboring countries. More than 7.5 million people do not have enough food to eat.

*Any goods, services, or funds provided by Salesian Missions to programs located in this country were administered in compliance with applicable laws and regulations, including sanctions administered by the U.S. Department of Treasury’s Office of Foreign Asset Control.

###

About Salesian Missions USA

Salesian Missions is headquartered in New Rochelle, NY, and is part of the Don Bosco Network—a worldwide federation of Salesian NGOs. The mission of the U.S.-based nonprofit Catholic organization is to raise funds for international programs that serve youth and families in poor communities around the globe. The Salesian missionaries are made up of priests, brothers and sisters, as well as laypeople—all dedicated to caring for poor children throughout the world in more than 130 countries and helping young people become self-sufficient by learning a trade that will help them gain employment. To date, more than 3 million youth have received services funded by Salesian Missions. These services and programs are provided to children regardless of race or religion. For more information, go to SalesianMissions.org.

Contact:

Hannah Gregory

media@salesianmissions.org

914-960-4642 (text messages OK)

Twitter: @MissionNewswire

Newswire: MissionNewswire.org

Press room: SalesianMissions.org/press

Share article on social media or email: